Linda Henry
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Linda Henry has a total of 374 co-authors. Here are the top co-authors by number of shared publications:
- Zobair Younossi
Beatty Liver and Obesity Research Program Inova Health System Falls Church Virginia USA
27 shared publications - Yusuf Yilmaz
Department of Gastroenterology, School of Medicine, Recep Tayyip Erdoğan University, Rize, Turkey
10 shared publications Maria Stepanova
The Global NASH/MASH Council, Washington, USA
9 shared publications- Mohamed El-Kassas
Endemic Medicine Department, Faculty of Medicine Capital University (Formerly Helwan University) Cairo Egypt
9 shared publications - Ming-Lung Yu
Center of Excellence for Metabolic Associated Fatty Liver Disease National Sun Yat‐sen University Kaohsiung Taiwan
7 shared publications - Khalid Alswat
Liver Disease Research Center, Department of Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia
6 shared publications
Latest Publications
- 22 October 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with health-related quality of life (HRQL) impairment, which can be exacerbated by pruritus, fatigue, and/or sleep disorders. We assessed the prevalence of significant pruritus, fatigue, and sleep disorders in patients with MASLD and evaluated their association with HRQL and work productivity loss. Methods: Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry. Clinical and HRQL (per CLDQ-MASH and WPAI:SHP questionnaires) data were analyzed according to the presence of significant pruritus, significant fatigue, and sleep disorders. Results: A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms. Patients with fatigue, pruritus, or sleep disorder were more likely to be female, have higher BMI, more metabolic comorbidities, and greater psychiatric burden. At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms. Multivariate analyses showed that significant pruritus and sleep disorders each independently predicted fatigue [OR=9.51 (8.0-11.3)] when both conditions were present. Pruritus was a strong predictor of sleep disorders [OR=2.90 (2.6-3.3)]. All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss. Conclusion: Clinically significant fatigue, pruritus, and sleep disorders are common in MASLD, having a negative impact on HRQL and a substantial economic burden.
- 22 October 2026
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
High Prevalence of Pruritus, Fatigue, and Sleep Disorders in MASLD Negatively Affects Health-related Quality of Life and Work Productivity
Background: Metabolic dysfunction–associated steatotic liver disease (MASLD) is associated with health-related quality of life (HRQL) impairment, which can be exacerbated by pruritus, fatigue, and/or sleep disorders. We assessed the prevalence of significant pruritus, fatigue, and sleep disorders in patients with MASLD and evaluated their association with HRQL and work productivity loss. Methods: Patients with MASLD were prospectively enrolled into the Global NAFLD/MASLD Registry. Clinical and HRQL (per CLDQ-MASH and WPAI:SHP questionnaires) data were analyzed according to the presence of significant pruritus, significant fatigue, and sleep disorders. Results: A total of 8034 patients with MASLD from 39 countries (age 54±12 years, 46% male, 50% type 2 diabetes, 39% advanced fibrosis) were included. At baseline, 25% reported significant pruritus, 35% significant fatigue, and 34% sleep disorders, and 10% had all 3 symptoms. Patients with fatigue, pruritus, or sleep disorder were more likely to be female, have higher BMI, more metabolic comorbidities, and greater psychiatric burden. At 1-year follow-up, over half of the patients with baseline symptoms continued to experience them, and 14% to 18% developed de novo symptoms. Multivariate analyses showed that significant pruritus and sleep disorders each independently predicted fatigue [OR=9.51 (8.0-11.3)] when both conditions were present. Pruritus was a strong predictor of sleep disorders [OR=2.90 (2.6-3.3)]. All 3 conditions, especially fatigue, were independently associated with significantly impaired HRQL and work productivity loss. Conclusion: Clinically significant fatigue, pruritus, and sleep disorders are common in MASLD, having a negative impact on HRQL and a substantial economic burden.
- 26 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Liver transplantation for cholestatic liver diseases: Trends in primary biliary cholangitis and primary sclerosing cholangitis in the US and Europe over two decades
Cholestatic liver diseases [primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)] are important indications for liver transplantation (LT). Adult LT recipients with PBC or PSC were identified from the European Liver Transplant Registry (ELTR) and U.S. Scientific Registry of Transplant Recipients (SRTR) (2000–2022). We assessed temporal trends in PBC/PSC prevalence among the LT population and used Cox models to identify variables associated with post-transplant mortality in PBC/PSC. A total of 22,034 LT recipients were included (PBC n=8774; PSC n=13,260). HCC was present in 5.4% PBC, and cholangiocarcinoma in 2.4% PSC. PBC recipients had more ascites and hepatic encephalopathy, higher MELD scores (20±9 vs. 19±9) ( p p 0.05). The declines in PBC-LTs were observed in both SRTR and ELTR; PSC has shown a recent increase in ELTR: 4.9% to 7.3% ( p p p <0.05). Liver transplantations for PBC have declined, which may reflect improved medical therapy; PSC has remained stable, with recent increases in Europe. Three-year post-transplant survival exceeds 85% for both groups and continues to improve.
- 26 August 2026
- Published by Wolters Kluwer Health in Liver Transplantation
Liver transplantation for cholestatic liver diseases: Trends in primary biliary cholangitis and primary sclerosing cholangitis in the US and Europe over two decades
Cholestatic liver diseases [primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC)] are important indications for liver transplantation (LT). Adult LT recipients with PBC or PSC were identified from the European Liver Transplant Registry (ELTR) and U.S. Scientific Registry of Transplant Recipients (SRTR) (2000–2022). We assessed temporal trends in PBC/PSC prevalence among the LT population and used Cox models to identify variables associated with post-transplant mortality in PBC/PSC. A total of 22,034 LT recipients were included (PBC n=8774; PSC n=13,260). HCC was present in 5.4% PBC, and cholangiocarcinoma in 2.4% PSC. PBC recipients had more ascites and hepatic encephalopathy, higher MELD scores (20±9 vs. 19±9) ( p p 0.05). The declines in PBC-LTs were observed in both SRTR and ELTR; PSC has shown a recent increase in ELTR: 4.9% to 7.3% ( p p p <0.05). Liver transplantations for PBC have declined, which may reflect improved medical therapy; PSC has remained stable, with recent increases in Europe. Three-year post-transplant survival exceeds 85% for both groups and continues to improve.
- Open Access
- 14 August 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- p. 1
Author Correction: The dynamic spectrum of steatotic liver disease: the global perspective
- 14 August 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- p. 1
Open AccessAuthor Correction: The dynamic spectrum of steatotic liver disease: the global perspective
- 7 August 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 23 (11) , 812-829
The dynamic spectrum of steatotic liver disease: the global perspective
- 7 August 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
- Vol. 23 (11) , 812-829
The dynamic spectrum of steatotic liver disease: the global perspective
- 8 July 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (8) , 2440-2447
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes
Background: Hepatitis B virus (HBV), hepatitis C virus (HCV), and metabolic dysfunction‐associated steatotic liver disease (MASLD) are common liver diseases. Clinical characteristics and patient‐reported outcomes (PROs) of HBV and HCV patients with/without superimposed MASLD were evaluated. Methods: Cross‐sectional study of clinical and PRO (FACIT‐Fatigue [FACIT‐F], Chronic Liver Disease Questionnaire [CLDQ], Work Productivity and Activity Impairment [WPAI] questionnaire) data from Global Liver Registry, HBV and HCV patients. MASLD was defined as Hepatic Steatosis Index (HSI) ≥ 36 with ≥ 1 cardiometabolic risk factor (overweight, type 2 diabetes, hypertension, and hyperlipidemia). Results: Among 4649 subjects, 2063 had HBV (48 ± 13 years; 57% male; 11% advanced fibrosis; 49% MASLD); 2586 had HCV (56 ± 14 years; 47% male; 18% advanced fibrosis; 47% MASLD). HBV with/without MASLD were similar in age, sex, and noncardiometabolic comorbidities (all p > 0.05) but those with MASLD had more advanced fibrosis ( p < 0.01) and significantly lower PRO scores: FACIT‐F Physical Well‐Being and Fatigue domains and all CLDQ (all p < 0.01) especially Fatigue domain (6% reduction in score range). HCV patients with MASLD were younger, more frequently female ( p < 0.01) with similar rates of advanced fibrosis, biopsy‐proven cirrhosis, and noncardiometabolic comorbidities (all p > 0.05). They had significantly lower scores in FACIT‐F Physical Well‐Being and all CLDQ domains (all p < 0.01); the greatest impairment was in Systemic Symptoms and Worry domains (6% reduction in score range). MASLD was independently associated with lower CLDQ scores in multivariate analysis ( p < 0.05). Conclusions: Approximately half of HBV or HCV patients had MASLD and reported significantly worse PROs, highlighting the importance of proactive metabolic assessment and management in patients with chronic viral hepatitis.
- 8 July 2026
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (8) , 2440-2447
Chronic Viral Hepatitis With MASLD: Implications for Clinical and Patient‐Reported Outcomes
Background: Hepatitis B virus (HBV), hepatitis C virus (HCV), and metabolic dysfunction‐associated steatotic liver disease (MASLD) are common liver diseases. Clinical characteristics and patient‐reported outcomes (PROs) of HBV and HCV patients with/without superimposed MASLD were evaluated. Methods: Cross‐sectional study of clinical and PRO (FACIT‐Fatigue [FACIT‐F], Chronic Liver Disease Questionnaire [CLDQ], Work Productivity and Activity Impairment [WPAI] questionnaire) data from Global Liver Registry, HBV and HCV patients. MASLD was defined as Hepatic Steatosis Index (HSI) ≥ 36 with ≥ 1 cardiometabolic risk factor (overweight, type 2 diabetes, hypertension, and hyperlipidemia). Results: Among 4649 subjects, 2063 had HBV (48 ± 13 years; 57% male; 11% advanced fibrosis; 49% MASLD); 2586 had HCV (56 ± 14 years; 47% male; 18% advanced fibrosis; 47% MASLD). HBV with/without MASLD were similar in age, sex, and noncardiometabolic comorbidities (all p > 0.05) but those with MASLD had more advanced fibrosis ( p < 0.01) and significantly lower PRO scores: FACIT‐F Physical Well‐Being and Fatigue domains and all CLDQ (all p < 0.01) especially Fatigue domain (6% reduction in score range). HCV patients with MASLD were younger, more frequently female ( p < 0.01) with similar rates of advanced fibrosis, biopsy‐proven cirrhosis, and noncardiometabolic comorbidities (all p > 0.05). They had significantly lower scores in FACIT‐F Physical Well‐Being and all CLDQ domains (all p < 0.01); the greatest impairment was in Systemic Symptoms and Worry domains (6% reduction in score range). MASLD was independently associated with lower CLDQ scores in multivariate analysis ( p < 0.05). Conclusions: Approximately half of HBV or HCV patients had MASLD and reported significantly worse PROs, highlighting the importance of proactive metabolic assessment and management in patients with chronic viral hepatitis.
- 9 June 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis
Background: /Aims : Direct-acting antiviral agents (DAA) effectively cure chronic hepatitis C (CHC) whereas curative therapy for chronic hepatitis B (CHB) is rare. We aimed to compare HCC incidence between suppressed CHB versus cured CHC patients with cirrhosis. Methods: We analyzed 5773 cirrhosis patients from 43 centers in 9 countries: 1877 with treated and suppressed CHB and 3896 with DAA-cured CHC using inverse probability treatment weight (IPTW) and competing risk analysis via Fine and Gray method. Results: After IPTW (on age, sex, ethnicity, study location, albumin, total bilirubin, creatinine, platelet, tobacco use, alcohol use, diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease, steatotic liver disease, obesity, and follow-up years), two study groups became similar in relevant characteristics. The 5-year cumulative HCC incidence was significantly higher in suppressed CHB compared to cured CHC (18.1% vs. 7.4%, P P P P P =0.954). On multivariable analysis, CHB suppression P P =0.04) were associated with higher HCC risk. Conclusion: HCC risk remains high in both treated and suppressed CHB cirrhosis and cured CHC cirrhosis. However, with prolonged CHB suppression, risk of HCC can be reduced, highlighting benefits of early treatment and viral suppression in patients with CHB.
- 9 June 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Higher incidence of hepatocellular carcinoma in suppressed hepatitis B cirrhosis compared to cured hepatitis C cirrhosis
Background: /Aims : Direct-acting antiviral agents (DAA) effectively cure chronic hepatitis C (CHC) whereas curative therapy for chronic hepatitis B (CHB) is rare. We aimed to compare HCC incidence between suppressed CHB versus cured CHC patients with cirrhosis. Methods: We analyzed 5773 cirrhosis patients from 43 centers in 9 countries: 1877 with treated and suppressed CHB and 3896 with DAA-cured CHC using inverse probability treatment weight (IPTW) and competing risk analysis via Fine and Gray method. Results: After IPTW (on age, sex, ethnicity, study location, albumin, total bilirubin, creatinine, platelet, tobacco use, alcohol use, diabetes mellitus, hypertension, hyperlipidemia, cardiovascular disease, steatotic liver disease, obesity, and follow-up years), two study groups became similar in relevant characteristics. The 5-year cumulative HCC incidence was significantly higher in suppressed CHB compared to cured CHC (18.1% vs. 7.4%, P P P P P =0.954). On multivariable analysis, CHB suppression P P =0.04) were associated with higher HCC risk. Conclusion: HCC risk remains high in both treated and suppressed CHB cirrhosis and cured CHC cirrhosis. However, with prolonged CHB suppression, risk of HCC can be reduced, highlighting benefits of early treatment and viral suppression in patients with CHB.
- 17 May 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (6) , e70188
Impact of Fatigue on Patient‐Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a Multinational Registry Study
Fatigue in chronic viral hepatitis may be associated with decreased health‐related quality of life and other patient‐reported outcomes (PROs). We evaluated the relationship between fatigue and PROs in patients with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Patients with CHB and CHC enrolled in the Global Liver Registry completed PRO instruments: FACIT‐F, CLDQ (for CHB), CLDQ‐HCV (for CHC), and WPAI:SHP. Fatigue was defined as FACIT‐F Fatigue Scale (FS) score < 30 (scale range: 0–52). Among 2888 patients from 14 countries, 1561 had CHB (mean age 47 ± 13 years; 60% male; 13% advanced fibrosis; 13% depression; 17% fatigue) and 1327 had CHC (50 ± 13 years; 47% male; 21% advanced fibrosis; 18% depression; 28% fatigue). CHB‐fatigue was associated with younger age, female, obesity, anxiety, depression (all p < 0.01) and worse PRO scores: CLDQ (scale 1–7): 4.1 ± 0.9 vs. 5.8 ± 0.9; FACIT score (range 0–108): 67.6 ± 14.5 vs. 87.7 ± 13.7; work productivity impairment (range 0–1): 0.33 ± 0.29 vs. 0.11 ± 0.22 (all p < 0.0001). Multivariable analysis confirmed the association of fatigue with lower PRO scores, impairment up to −23% ( p < 0.01). CHC‐fatigue was associated with female sex, obesity, type 2 diabetes, anxiety, depression (all p < 0.05) and worse PRO scores: CLDQ‐HCV: 3.8 ± 1.0 vs. 5.5 ± 1.0; FACIT: 61.8 ± 14.1 vs. 85.6 ± 14.5; work productivity impairment: 0.49 ± 0.32 vs. 0.17 ± 0.25 (all p < 0.0001). In multivariable models, fatigue remained associated with reduced PRO scores, impairment up to −33% ( p < 0.01). Almost one in five patients with chronic viral hepatitis report significant fatigue, which is associated with substantial PRO and work productivity impairment. Routine assessment for and management of fatigue in CHC or CHB care is essential.
- 17 May 2026
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 33 (6) , e70188
Impact of Fatigue on Patient‐Reported Outcomes and Work Productivity in Chronic Hepatitis B and C: Insights From a Multinational Registry Study
Fatigue in chronic viral hepatitis may be associated with decreased health‐related quality of life and other patient‐reported outcomes (PROs). We evaluated the relationship between fatigue and PROs in patients with chronic hepatitis B (CHB) and chronic hepatitis C (CHC). Patients with CHB and CHC enrolled in the Global Liver Registry completed PRO instruments: FACIT‐F, CLDQ (for CHB), CLDQ‐HCV (for CHC), and WPAI:SHP. Fatigue was defined as FACIT‐F Fatigue Scale (FS) score < 30 (scale range: 0–52). Among 2888 patients from 14 countries, 1561 had CHB (mean age 47 ± 13 years; 60% male; 13% advanced fibrosis; 13% depression; 17% fatigue) and 1327 had CHC (50 ± 13 years; 47% male; 21% advanced fibrosis; 18% depression; 28% fatigue). CHB‐fatigue was associated with younger age, female, obesity, anxiety, depression (all p < 0.01) and worse PRO scores: CLDQ (scale 1–7): 4.1 ± 0.9 vs. 5.8 ± 0.9; FACIT score (range 0–108): 67.6 ± 14.5 vs. 87.7 ± 13.7; work productivity impairment (range 0–1): 0.33 ± 0.29 vs. 0.11 ± 0.22 (all p < 0.0001). Multivariable analysis confirmed the association of fatigue with lower PRO scores, impairment up to −23% ( p < 0.01). CHC‐fatigue was associated with female sex, obesity, type 2 diabetes, anxiety, depression (all p < 0.05) and worse PRO scores: CLDQ‐HCV: 3.8 ± 1.0 vs. 5.5 ± 1.0; FACIT: 61.8 ± 14.1 vs. 85.6 ± 14.5; work productivity impairment: 0.49 ± 0.32 vs. 0.17 ± 0.25 (all p < 0.0001). In multivariable models, fatigue remained associated with reduced PRO scores, impairment up to −33% ( p < 0.01). Almost one in five patients with chronic viral hepatitis report significant fatigue, which is associated with substantial PRO and work productivity impairment. Routine assessment for and management of fatigue in CHC or CHB care is essential.
- 6 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70619
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey
Background and Aims: Although pregnant people are a WHO priority population for hepatitis C (HCV) elimination, there is limited guidance on HCV treatment in pregnancy. Emerging data suggests direct acting antiviral (DAA) therapy is safe and effective. We performed a multinational survey among gastro‐hepatologists (GI‐Hep), infectious disease (ID) specialists, obstetricians‐gynaecologists (ob‐gyns), and general practitioners (GP) to evaluate current perspectives on HCV treatment in pregnancy. Methods: A 39‐item survey was designed by experts at The Global Liver Council, the American College of Obstetricians and Gynaecologists, and the Coalition for Global Hepatitis Elimination and distributed electronically. Survey responses were compared across medical specialties and regions. Results: A total of 651 participants from all WHO regions representing 58 countries completed the survey: GI‐Hep: 46%, GP‐ID: 36%, ob‐gyns: 18%. Only 25% would consider treating HCV during pregnancy, with significant differences by specialty. Main reasons for not considering DAAs in pregnancy were insufficient safety data (27%) and no clear guidelines for HCV treatment (32%). The highest acceptance of DAA use in pregnancy was in North America (45% vs. < 20% in other regions ( p < 0.01)). Predictors of a greater willingness to treat HCV in pregnancy were having ≥ 10% of practice population with injection drug use (aOR: 2.31; 95% CI: 1.49–3.60; p = 0.0002). GI‐Hep specialty was associated with a lower willingness (aOR: 0.47; 95% CI: 0.28–0.78; p = 0.004). Conclusions: Despite relatively high levels of HCV knowledge, few participants have experience with HCV treatment in pregnancy or would consider such treatment. Further availability of safety evidence and the inclusion of specific recommendations in guidelines could increase uptake of DAAs for pregnant individuals.
- 6 April 2026
- Published by Wiley in Liver International
- Vol. 46 (5) , e70619
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey
Background and Aims: Although pregnant people are a WHO priority population for hepatitis C (HCV) elimination, there is limited guidance on HCV treatment in pregnancy. Emerging data suggests direct acting antiviral (DAA) therapy is safe and effective. We performed a multinational survey among gastro‐hepatologists (GI‐Hep), infectious disease (ID) specialists, obstetricians‐gynaecologists (ob‐gyns), and general practitioners (GP) to evaluate current perspectives on HCV treatment in pregnancy. Methods: A 39‐item survey was designed by experts at The Global Liver Council, the American College of Obstetricians and Gynaecologists, and the Coalition for Global Hepatitis Elimination and distributed electronically. Survey responses were compared across medical specialties and regions. Results: A total of 651 participants from all WHO regions representing 58 countries completed the survey: GI‐Hep: 46%, GP‐ID: 36%, ob‐gyns: 18%. Only 25% would consider treating HCV during pregnancy, with significant differences by specialty. Main reasons for not considering DAAs in pregnancy were insufficient safety data (27%) and no clear guidelines for HCV treatment (32%). The highest acceptance of DAA use in pregnancy was in North America (45% vs. < 20% in other regions ( p < 0.01)). Predictors of a greater willingness to treat HCV in pregnancy were having ≥ 10% of practice population with injection drug use (aOR: 2.31; 95% CI: 1.49–3.60; p = 0.0002). GI‐Hep specialty was associated with a lower willingness (aOR: 0.47; 95% CI: 0.28–0.78; p = 0.004). Conclusions: Despite relatively high levels of HCV knowledge, few participants have experience with HCV treatment in pregnancy or would consider such treatment. Further availability of safety evidence and the inclusion of specific recommendations in guidelines could increase uptake of DAAs for pregnant individuals.
- Open Access
- 26 February 2026
- Vol. 10 (3)
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.
Resmetirom is approved for MASH F2-F3 fibrosis. Health-related quality of life (HRQL) was assessed in patients with MASH treated with resmetirom. Patients with MASH enrolled in MAESTRO-NAFLD-1 (NCT04197479) and the 52-week open-label extension study (year 2). HRQL was assessed using LDQoL and CLDQ-NAFLD. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) response definition for early MASH: a decrease ≥30% from baseline; MASH cirrhosis ≥20% decrease (if baseline MRI-PDFF >5%). MAESTRO-NAFLD-1 included 180 patients with MASH cirrhosis and 1143 with early MASH [baseline MRI-PDFF ≥8%, vibration-controlled transient elastography (VCTE) ≥5.5 kPa <8.5 kPa] treated with 80 mg or 100 mg resmetirom or placebo or 100 mg open-label resmetirom. Baseline HRQL for MASH cirrhosis was significantly lower (up to -15% of score range) for all 6 domains of CLDQ-NAFLD and 13/17 domains of LDQoL (p<0.05). MASH cirrhosis, by week 24 of resmetirom treatment year 1, had improvements in Worry (CLDQ-NAFLD) and Health Distress (LDQoL) up to +4% of score range, sustained through week 52 and throughout year 2 (day 1, week 12, week 28) (p0.05). Early MASH patients with MRI-PDFF response experienced Abdominal and Worry score (up to +6%) improvements-greater than placebo or nonresponders. Early MASH and MASH cirrhosis treated with resmetirom experience improvement in some disease-specific HRQL scores.
- 26 February 2026
- Vol. 10 (3)
Open AccessImprovement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.
Resmetirom is approved for MASH F2-F3 fibrosis. Health-related quality of life (HRQL) was assessed in patients with MASH treated with resmetirom. Patients with MASH enrolled in MAESTRO-NAFLD-1 (NCT04197479) and the 52-week open-label extension study (year 2). HRQL was assessed using LDQoL and CLDQ-NAFLD. Magnetic resonance imaging-proton density fat fraction (MRI-PDFF) response definition for early MASH: a decrease ≥30% from baseline; MASH cirrhosis ≥20% decrease (if baseline MRI-PDFF >5%). MAESTRO-NAFLD-1 included 180 patients with MASH cirrhosis and 1143 with early MASH [baseline MRI-PDFF ≥8%, vibration-controlled transient elastography (VCTE) ≥5.5 kPa <8.5 kPa] treated with 80 mg or 100 mg resmetirom or placebo or 100 mg open-label resmetirom. Baseline HRQL for MASH cirrhosis was significantly lower (up to -15% of score range) for all 6 domains of CLDQ-NAFLD and 13/17 domains of LDQoL (p<0.05). MASH cirrhosis, by week 24 of resmetirom treatment year 1, had improvements in Worry (CLDQ-NAFLD) and Health Distress (LDQoL) up to +4% of score range, sustained through week 52 and throughout year 2 (day 1, week 12, week 28) (p0.05). Early MASH patients with MRI-PDFF response experienced Abdominal and Worry score (up to +6%) improvements-greater than placebo or nonresponders. Early MASH and MASH cirrhosis treated with resmetirom experience improvement in some disease-specific HRQL scores.
- Open Access
- 20 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (3) , 101680
Longitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the US
- 20 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (3) , 101680
Open AccessLongitudinal risk of cirrhosis by steatotic liver disease subtype among 1.5 million individuals in the US